Neuropathy Screening and Diagnosis Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Neuropathy Screening and Diagnosis Market is segmented By Disease Type (Autonomic, Diabetic Neuropathy, Peripheral Neuropathy, Focal Neuropathy, Poly Neuropathy), By Diagnosis Test (Sensory Testing, Nerve Conduction Testing, Electromyography, Autonomic Testing, Skin Biopsy, MRI Scanning, Others), By End-User (Hospitals, Neurology Clinics, Academic and Research Institutes, Others) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overview

The Global Neuropathy Screening and Diagnosis Market reached US$ 4.2 billion in 2023 and is expected to reach US$ 7.1 billion by 2031, growing at a CAGR of 6.7% during the forecast period 2024-2031.

Neuropathy is a condition when nerve damage leads to pain, weakness, numbness, or tingling in one or more parts of one’s body. There is a broad classification in neuropathy and neuropathy can be caused by diabetes, autoimmune diseases, chemotherapy, intake of toxins, etc. The symptoms and treatment depend upon the type of nerves that are being affected.

Some types of neuropathies can be prevented such as neuropathy associated with alcohol abuse or very restrictive diets. Physical trauma is a common cause of injury to the nerves. This can include car accidents, falls, or fractures. Inactivity, or holding still too long in one position, can also cause neuropathy. Increased pressure on the median nerve, a nerve in the wrist that supplies feeling and movement to the hand, causes carpal tunnel syndrome.

Market Scope

For more details on this report - Request for Sample

Market Dynamics: Drivers

Increasing prevalence of neuropathy 

The demand for the neuropathy screening and diagnosis market is driven by multiple factors. The rising prevalence of various types of neuropathy especially in the older populations propels the market growth. 

Furthermore, the demand for neuropathy diagnostics and screening will be fueled by the growing advancements in the field of diagnostics and research. For instance, according to the National Library of Medicine article published in October 2022, around 2.4% of people of the entire global population are affected by peripheral neuropathy. The prevalence of neuropathy has increased to 8% in the older populations. 

In epidemiological studies from India from various regions, the overall prevalence of peripheral neuropathy varied from 5 to 2400 per 10,000 population in various community studies. India is composed of a multiethnic, multicultural population who are exposed to different adverse environmental factors such as arsenic and lead. Use of different chemotherapeutic agents with a propensity to affect peripheral nerves, increasing methods of diagnosis of connective tissue disorders, and the use of immunomodulating drugs, the growing aging population is expected to change the spectrum and burden of peripheral neuropathy in the community.

Prevalence of neuropathy in diabetic patients ranges from around 10.5% to 32.2% in various studies across India and up to 50% of patients will eventually develop neuropathy during their disease according to Western literature. 

Restraints

Factors such as high cost associated with the screening and diagnostic techniques, lack of awareness among people, and stringent regulatory compliance are expected to hamper the market.

Market Segment Analysis

The neuropathy screening and diagnosis market is segmented based on disease type, diagnosis test, end-user, and region.   

The segment electromyography accounted for approximately 47.3% of the neuropathy screening and diagnosis market share

Electromyography (EMG) is a diagnostic technique used to assess the health of muscles and the nerve cells that control them (motor neurons). EMG is primarily used to diagnose muscle and nerve disorders. It measures the electrical activity of muscles both at rest and during contraction. During an EMG, small needles (electrodes) are inserted into the muscles being tested. These electrodes detect the electrical activity generated by muscle cells when they contract.

EMG is highly accurate in detecting abnormal electrical activity in muscles and nerves. Specific values may vary depending on the condition being tested, but EMG is generally considered sensitive and specific for diagnosing neuromuscular disorders. EMG is also used in research settings to study muscle function, fatigue, and performance. It informs treatment plans, such as for physical therapy or surgical interventions.

EMG is generally considered safe when performed by trained professionals. Risks include minor discomfort, bleeding, or infection at the needle insertion site. Advances in technology continue to improve EMG accuracy and reduce patient discomfort, such as the development of wireless and miniaturized electrodes.

For instance, in January 2024, a collaborative research team headed by Professors Jae-Woong Jung of the KAIST School of Electrical Engineering (EE) and Jung Kim of the KAIST Department of Mechanical Engineering (ME) announced that they had effectively created a stretchable and adhesive microneedle sensor that is capable of high-level electrical physiological signal detection that is independent of the user’s skin condition. 

Market Geographical Share

North America accounted for approximately 42.8% of the neuropathy screening and diagnosis market share 

North America region is expected to hold the largest market share over the forecast period. The rising incidence of neuropathy, growing awareness among people, and the presence of major players in this region help to propel the market.

According to Yale Medicine.org, more than 20 million Americans are being affected by neuropathy. In this region increase in diabetic cases is also one of the reasons for the cause of diabetic neuropathy which is one of the major types of neuropathy. People having autoimmune diseases and cancer are also affected by neuropathy in some cases.

It is also estimated that 47% of the people having diabetes are being affected by diabetic neuropathy in the US. According to effectivehealthcare.gov, around 9.3% of people are affected by various types of neuropathy in the US. In recent times there have been a lot of advancements in the diagnostic techniques of neuropathy in the US. All these factors together led to North America being accounted for the largest market share over the forecast period.

Market Segmentation

By Disease Type

• Autonomic Neuropathy
• Diabetic Neuropathy
• Peripheral Neuropathy
• Focal Neuropathy
• Poly Neuropathy

By Diagnosis Test

• Sensory Testing
• Nerve Conduction Testing
• Electromyography
• Autonomic Testing
• Skin Biopsy
• MRI Scanning
• Others

By End-User

• Hospitals
• Neurology Clinics
• Academic And Research Centers
• Others

By Region

• North America 
• The U.S.
• Canada
• Mexico 
• Europe 
• Germany
• U.K.
• France
• Spain
• Italy
• Rest of Europe 
• South America 
• Brazil
• Argentina
• Rest of South America 
• Asia-Pacific 
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 
• Middle East and Africa

Market Competitive Landscape

The major global players in the neuropathy screening and diagnosis market include Eli Lilly and Company, Reddy’s Laboratories, Pfizer Inc. Inc., Cipla, Abbott Laboratories, Lupin Ltd., NeuroBo Pharmaceuticals Inc., NeuroMetrix Inc., Glenmark Pharmaceuticals, Teva Pharmaceutical Industries among others.

Key Developments

• In January 2023, NeuroMetrix announced the launch and commercial availability of DNP Check 2.0. It is the company’s latest point-of-care device that leverages gold-standard nerve conduction technology to detect peripheral neuropathy.  DPN Check 2.0 provides rapid patient screening with quantitative measurement of peripheral nerve function.
• In January 2024, Takeda Pharmaceuticals gammagard liquid was approved by the US FDA for adults with chronic inflammatory demyelinating polyneuropathy. It is a subtype in the polyneuropathy category of classification. 
• In June 2023, Abbot’s spinal cord stimulation for people with painful diabetic peripheral neuropathy is being approved by the FDA. 

Why Purchase the Report?

• To visualize the neuropathy screening and diagnosis market segmentation based on disease type, diagnosis test, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of neuropathy screening and diagnosis market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The neuropathy screening and diagnosis market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies